Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma
Keywords:
melanoma, anti-PD-1, anti-LAG-3, adverse eventsReferences
Tawbi HA, Schadendorf D, Lipson EJ, et al. RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24-34. DOI: 10.1056/NEJMoa2109970. PMID: 34986285. PMCID: PMC9844513.
Seth R, Agarwala SS, Messersmith H, et al. Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023;41(30):4794-20. DOI: 10.1200/JCO.23.01136. PMID: 37579248.
Litaiem N, Mansour Y, Jones M, et al. Dermoscopic signs of lichen planus. BMJ Case Rep. 2016;2016:bcr2015213923. DOI: 10.1136/bcr-2015-213923. PMID: 26759406. PMCID: PMC4716428.
National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), ver. 5.0. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf Accessed April 3, 2023.
Nikolaou V, Tsimpidakis A, Stratigos A. Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma. Cancers (Basel). 2023;15(7):2084. DOI: 10.3390/cancers15072084. PMID: 37046745. PMCID: PMC10093334.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Marek Pasek, Eva Sticová, Emanuel Marques, Vojtěch Tretera, Petr Arenberger, Monika Arenbergerová

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.